Citations

Clear

6273 citation(s) found for "To, Andrew".

HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease
Yogeshwar, Selina , Muñiz‐Castrillo, Sergio , Sabater, Lídia , Peris-Sempere, Vicente, Mallajosyula, Vamsee , Guo, Luo, Yan, Han , Lin, Ling , Bueno, Flavia Fagundes, Ji, Xuhuai , Picard, Géraldine , Pinto, Anne Laurie, Heidbreder, Anna , Dalmau, Josep , Santamaría, Joan , Iranzo, Alex, Schreiner, Bettina , Giannoccaro, Maria Pia , Kimura, Akio , Ono, Yoya , Bonello, Michael , Nigro, Pasquale , Prüß, Harald , McKeon, Andrew, Irani, Sarosh R. , Gaig, Carles , Mignot, Emmanuel , Luo, Guo , Yogeshwar, Selina M , Höftberger, Romana , Iranzo, Alex , Dinoto, Alessandro , Irani, Sarosh R , Honnorat, Jérôme , Finke, Carsten , Mignot, Emmanuel , Muñiz-Castrillo, Sergio , Dalmau, Josep O , Heidbreder, Anna , Luo, Guo, Yu, Eric , Zhang, Jing , Rogemond, Véronique , Graus, Francesc , Liguori, Rocco , Shimohata, Takayoshi , Binks, Sophie , Mariotto, Sara , Dinoto, Alessandro , Hartmann, Christian Johannes , Tambasco, Nicola , McKeon, Andrew , Davis, Mark M. , Honnorat, Jérôme

Mayo Clinic

Brain | March 1, 2024 | Volume: 147 | Issue: 7 | Pages: 2579-2592

10.1093/brain/awae048 | PMID 38425314 Get It

Abstract Anti-IgLON5 disease is a rare and likely underdiagnosed subtype of autoimmune encephalitis. The disease displays a heterogeneous phenotype that includes sleep, movement and bulbar-associated dysfunction. The presence of IgLON5-antibodies in CSF/serum, together with a strong association with HLA-DRB1*10:01∼DQB1*05:01, supports an autoimmune basis. In this study, a multicentric human leukocyte antigen (HLA) study of 87 anti-IgLON5 patients revealed a stronger association with HLA-DQ than HLA-DR. Specifically, we identified a predisposing rank-wise association with HLA-DQA1*01:05∼DQB1*05:01, HLA-DQA1*01:01∼DQB1*05:01 and HLA-DQA1*01:04∼DQB1*05:03 in 85% of patients. HLA sequences and binding cores for these three DQ heterodimers were similar, unlike those of linked DRB1 alleles, supporting a causal link to HLA-DQ. This association was further reflected in an increasingly later age of onset across each genotype group, with a delay of up to 11 years, while HLA-DQ-dosage dependent effects were also suggested by reduced risk in the presence of non-predisposing DQ1 alleles. The functional relevance of the observed HLA-DQ molecules was studied with competition binding assays. These proof-of-concept experiments revealed preferential binding of IgLON5 in a post-translationally modified, but not native, state to all three risk-associated HLA-DQ receptors. Further, a deamidated peptide from the Ig2-domain of IgLON5 activated T cells in two patients, compared with one control carrying HLA-DQA1*01:05∼DQB1*05:01. Taken together, these data support a HLA-DQ-mediated T-cell response to IgLON5 as a potentially key step in the initiation of autoimmunity in this disease.
Genetic and Pharmacological Inhibition of PAPP-A Reduces Bleomycin-Induced Pulmonary Fibrosis in Aged Mice via Reduced IGF Signaling
Conover, Cheryl A. , Bale, Laurie K., West, Sally A., Oxvig, Claus , Andersen, Kristian S., Roden, Anja C. , Haak, Andrew J.

Mayo Clinic

Aging Biology | February 28, 2024 | Volume: 1 | Issue: 1 | Pages: 20240023

10.59368/agingbio.20240023 | PMID 40110162 Get It

American Association of Plastic Surgeons Consensus on Breast Implant–Associated Anaplastic Large-Cell Lymphoma
Clemens, Mark W. , Myckatyn, Terence M. , McCarthy, Colleen M., Holmes, Sari D. , Phillips, Linda G., Napoli, Arianna Di , Feldman, Andrew L. , Jaffe, Elaine S. , Haymaker, Cara , Horwitz, Steven M. , Hunt, Kelly K. , Kadin, Marshall E. , Miranda, Roberto N. , Prince, H. Miles , Pompeo, Fabio Santanelli di

Mayo Clinic

Plastic & Reconstructive Surgery | February 27, 2024 | Volume: 154 | Issue: 3 | Pages: 473-483

10.1097/prs.0000000000011370 | PMID 38412359 Get It

Background: In the absence of high-quality evidence, there is a need for guidelines and multidisciplinary consensus recommendations on breast implant–associated anaplastic large-cell lymphoma (BIA-ALCL). The purpose of this expert consensus conference was to evaluate the existing evidence regarding the diagnosis and management of BIA-ALCL caused by textured implants. This article aims to provide evidence-based recommendations regarding the management and prevention of BIA-ALCL. Methods: A comprehensive search was conducted in the MEDLINE, Cochrane Library, and Embase databases, and supplemented by manual searches of relevant English-language articles and “related articles” sections. Studies focusing on breast surgery and lymphoma associated with breast implants were included for analysis. Meta-analyses were performed and reviewed by experts selected by the American Association of Plastic Surgeons using a Delphi consensus method. Results: A total of 840 articles published between January of 2011 and January of 2023 were initially identified and screened. The full text of 188 articles was assessed. An additional 43 articles were excluded for focus, and 145 articles were included in the synthesis of results, with 105 of them being case reports or case series. The analysis encompassed a comprehensive examination of the selected articles to determine the incidence, risk factors, clinical presentation, diagnostic approaches, and treatment modalities related to BIA-ALCL. Conclusions: Plastic surgeons should be aware of the elevated risks by implant surface type, implement appropriate patient surveillance, and follow the recommendations outlined in this statement to ensure patient safety and optimize outcomes. Ongoing research on the pathogenesis, genetic drivers, and preventative and prophylactic measures for BIA-ALCL is crucial for improving patient care. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, V.
Antidepressant Effects of Aerobic Exercise After Spinal Cord injury
Mercier, Hannah W. , Picard, Glen, Solinsky, Ryan , Solinsky, Ryan , Linnman, Clas , Taylor, Andrew J.

Mayo Clinic

No container title available | February 27, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3875889/v1 Get It

Abstract Study Design: Secondary outcome measures analysis of a randomized, controlled study. Objectives: To assess the effects of hybrid-functional electrical stimulation (FES) rowing, arms only (AO) rowing and waitlist (WL) controls on pain, pain interference, and depression in individuals with spinal cord injury (SCI). Setting: Outpatient rehabilitation networks Methods: 44 participants were randomly assigned to FES (n = 19), AO (n= 12) or WL (n=13). The FES group completed 6 months of rowing scheduled 3 times per week. Individuals in the AO and WL groups were allowed to cross over to FES rowing after 6 months and were included in subsequent analyses of the effects of FES rowing. Rowing distance and intensity was logged, and maximal oxygen consumption (VO2max) measures were obtained before and after the intervention. Changes in the Patient-Reported Outcomes Measurement Information System (PROMIS-56) derived pain interference, pain, and depression scores were analyzed. Results: FES-rowing led to modest improvements in depression, AO led to modest improvements in pain intensity, and WL did not improve pain nor depression. After incorporating individuals who crossed over to FES rowing, we observed modest but significant improvement in depression scores but not in pain. Among the participants who benefited from the FES intervention, the reduction in depression was correlated to the average weekly rowing distance (r2=0.79 p=0.0001). Conclusions: 6 months of FES rowing spent in a supportive environment can help persons with spinal cord injuries alleviate moderate depression in a dose-dependent manner.
Primary Pulmonary Myxoid Sarcoma and Thoracic Angiomatoid Fibrous Histiocytoma
Kerper, Allison L. , Larsen, Brandon T. , Folpe, Andrew L. , Roden, Anja C. , Torres‐Mora, Jorge , Aubry, Marie‐Christine, Kerper, Allison , Boland, Jennifer M. , Lo, Ying‐Chun , Aubry, Marie-Christine

Mayo Clinic

American Journal of Surgical Pathology | February 26, 2024 | Volume: 48 | Issue: 5 | Pages: 562-569

10.1097/pas.0000000000002189 | PMID 38407279 Get It

Primary pulmonary myxoid sarcoma (PPMS) and thoracic angiomatoid fibrous histiocytoma (AFH) are rare neoplasms with EWSR1 fusions and overlapping morphology. Both tumor types often show epithelial membrane antigen expression, but AFH characteristically co-expresses desmin. We encountered a case of PPMS with the unexpected finding of patchy, strong anaplastic lymphoma kinase (ALK) (previously reported in AFH) and synaptophysin expression. We evaluated a cohort of PPMS and thoracic AFH with systematic morphologic comparison and surveyed for aberrant expression of ALK and synaptophysin. Medical records and slides were reviewed for 16 molecularly confirmed cases of PPMS (n=5) and thoracic AFH (n=11). Each case was scored for morphologic characteristics typical of PPMS and/or AFH. ALK, synaptophysin, chromogranin, desmin, and epithelial membrane antigen immunostains were performed on cases with available tissue. AFH and PPMS cases showed similar age at presentation and long-term tumor behavior. Almost all cases of PPMS and AFH had a fibrous pseudocapsule and lymphoid rim. All PPMS had myxoid stroma and reticular growth pattern, but these features were also present in a subset of AFH. Synaptophysin expression was present in 6 of 11 AFH and 1 of 5 PPMS; all tested cases were negative for chromogranin (n=15). One case of AFH and 1 case of PPMS showed focally strong coexpression of synaptophysin and ALK. AFH and PPMS show considerable clinicopathologic overlap. When supportive, the immunohistochemical findings described may aid in diagnosis before molecular confirmation. PPMS and AFH may be morphologic variants of the same clinicopathologic entity, which can show more immunophenotypic variability than previously reported.
Circadian rhythm and whole gut transit in mice
Laible, Emma, Wegner, Andrew, Knutson, Kaitlyn R. , Kacmaz, Halil, Garramone, Gwyneth K., Gogineni, Kamalika , Matveyenko, Aleksey V. , Linden, David R. , Farrugia, Gianrico , Beyder, Arthur , Knutson, Kaitlyn, Matveyenko, Aleksey, Linden, D R , Beyder, Arthur , Laible, Emma

Mayo Clinic

Neurogastroenterology & Motility | February 24, 2024 | Volume: 36 | Issue: 4 | Pages: No page available

10.1111/nmo.14771 | PMID 38396340 Get It

AbstractBackgroundIn preclinical studies whole gut transit (WGT) in mice is a gold‐standard “leading‐edge” approach that measures the time between orogastric gavage of carmine red and defecation of the first carmine red pellet. Transit studies in humans are performed during the active day because GI motility and transit are suppressed during the night. Since mice are nocturnal, WGT studies traditionally done during the day occur during their rest phase. How circadian rhythm affects WGT in mice is not known.MethodsWe used an automated approach for high temporal resolution uninterrupted testing of mouse WGT and activity. We housed wild‐type Bl6/C57 mice under the standard 12 h light–dark cycles. At 8 weeks, we performed carmine red orogastric gavage and assessed WGT during Light (rest) conditions. Then, we exposed mice to a reverse 12 h light–dark cycle for 2 weeks and tested them in the Dark (active) under red light conditions. Timelapse videos were analyzed to quantify activity and to timestamp all pellets, and multiple parameters were analyzed.Key ResultWhen complementary light cycle reversal experiments were performed, we found a significant increase in mouse activity when mice were tested during their Dark (active) phase, compared to their Light (rest) phase. In mice tested in the Active phase compared to the Rest phase, we found a significant acceleration in WGT, increased rate and total number of pellets produced, and more pellet clustering. These data show that the mice tested in the Active phase have important differences in activity that correlate with multiple alterations in gastrointestinal transit.Conclusion & InferencesDuring the Active phase mice have faster WGT, produce more pellets, and cluster their output compared to testing in the Rest phase. Like in humans, circadian rhythm is an important consideration for transit studies in mice, and a simple reverse light cycle approach facilitates further studies on the role of circadian rhythm in GI motility.
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
Wang, Guoqiao , Li, Yan , Xiong, Chengjie , Gordon, Brian A. , Hassenstab, Jason , Aschenbrenner, Andrew J. , Clifford, David B. , Libre‐Guerra, Jorge J., Shi, Xinyu , Mummery, Catherine J. , Dyck, Christopher H. van , Day, Gregg, Ringman, John M. , Fox, Nick C. , Bittner, Tobias , Team, for the DIAN‐TU Study, Day, Gregory S. , Gordon, Brian A , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Aschenbrenner, Andrew J , Xiong, Chengjie , Benzinger, Tammie L.S. , McDade, Eric , Lah, James J. , Honig, Lawrence S. , Day, Gregg, Brooks, William S. , Suzuki, Kazushi , Jucker, Mathias , Delmar, Paul , Bateman, Randall J. , Team, for the DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | February 24, 2024 | Volume: 20 | Issue: 4 | Pages: 2698-2706

10.1002/alz.13735 | PMID 38400532 Get It

AbstractINTRODUCTIONIncreasing evidence suggests that amyloid reduction could serve as a plausible surrogate endpoint for clinical and cognitive efficacy. The double‐blind phase 3 DIAN‐TU‐001 trial tested clinical and cognitive declines with increasing doses of solanezumab or gantenerumab.METHODSWe used latent class (LC) analysis on data from the Dominantly Inherited Alzheimer Network Trials Unit 001 trial to test amyloid positron emission tomography (PET) reduction as a potential surrogate biomarker.RESULTSLC analysis categorized participants into three classes: amyloid no change, amyloid reduction, and amyloid growth, based on longitudinal amyloid Pittsburgh compound B PET standardized uptake value ratio data. The amyloid‐no‐change class was at an earlier disease stage for amyloid amounts and dementia. Despite similar baseline characteristics, the amyloid‐reduction class exhibited reductions in the annual decline rates compared to the amyloid‐growth class across multiple biomarker, clinical, and cognitive outcomes.DISCUSSIONLC analysis indicates that amyloid reduction is associated with improved clinical outcomes and supports its use as a surrogate biomarker in clinical trials.Highlights We used latent class (LC) analysis to test amyloid reduction as a surrogate biomarker. Despite similar baseline characteristics, the amyloid‐reduction class exhibited remarkably better outcomes compared to the amyloid‐growth class across multiple measures. LC analysis proves valuable in testing amyloid reduction as a surrogate biomarker in clinical trials lacking significant treatment effects.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Jonasch, Eric, Alva, Ajjai , Bagshaw, H.P. , Costello, Brian A. , Derweesh, Ithaar , Desai, Arpita, Ged, Yasser , Johnson, Michael P. , King, Jennifer , Kyriakopoulos, Christos E. , Lara, Primo N. , Lau, Clayton, Lewis, Bryan , Mortazavi, Amir , Ponsky, Lee , Ramalingam, Sundhar, Shuch, Brian , Smith, Zachary L. , Sosman, Jeffrey A. , Zibelman, Matthew R. , Schonfeld, Ryan, Stein, MaryElizabeth , Gurski, Lisa A., Motzer, Robert J. , Agarwal, Neeraj , Baine, Michael J. , Beckermann, Kathryn E. , Carlo, Maria I. , Choueiri, Toni K. , George, Saby , Gore, John L. , Gunn, Andrew, Haas, Naomi B , Johnson, Michael, Kapur, Payal , King, Jennifer, Lam, Elaine T. , Madoff, David C. , Manley, Brandon J. , Michaelson, M. Dror , Sweis, Randy F.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 23, 2024 | Volume: 22 | Issue: 1 | Pages: 4-16

10.6004/jnccn.2024.0008 | PMID 38394781 Get It

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced RCC and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations
Pemmaraju, Naveen , Madanat, Yazan F. , Rizzieri, David A. , Fazal, Salman, Rampal, Raajit K. , Mannis, Gabriel N. , Wang, Eunice S. , Foran, James M. , Lane, Andrew A. , Rizzieri, David A , Rampal, Raajit K , Foran, James M , Wang, Eunice S. , Madanat, Yazan , Lane, Andrew A

Mayo Clinic

Leukemia & Lymphoma | February 23, 2024 | Volume: 65 | Issue: 5 | Pages: 548-559

10.1080/10428194.2024.2305288 | PMID 38391126 Get It

The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Luque, Laura F. Mendez , Avelar‐Barragan, Julio , Nguyen, Hellen , Nguyen, Jenny , Soyfer, Eli M. , Liu, Jiarui , Chen, Jane H. , Mehrotra, Nitya , Huang, Xin , Kosiorek, Heidi , Dueck, Amylou C. , Heide, Elena , Lem, Melinda , Alaoui, Kenza El , Mas, Eduard , Scherber, Robyn M. , Whiteson, Katrine , Dueck, A. C. , Mendez Luque, Laura F , Kosiorek, Heidi E , Himstead, Alexander , Heide, Elena , Lem, Melinda , El Alaoui, Kenza , Mas, Eduard , Scherber, Robyn M , Mesa, Ruben , Whiteson, Katrine L , Odegaard, Andrew , Fleischman, Angela G , Mesa, Ruben A. , Fleischman, Angela G.

Mayo Clinic

Cancer Research Communications | February 23, 2024 | Volume: 4 | Issue: 3 | Pages: 660-670

10.1158/2767-9764.crc-23-0380 | PMID 38391189 Get It

Abstract Purpose: Chronic inflammation is integral to myeloproliferative neoplasm (MPN) pathogenesis. JAK inhibitors reduce cytokine levels, but not without significant side effects. Nutrition is a low-risk approach to reduce inflammation and ameliorate symptoms in MPN. We performed a randomized, parallel-arm study to determine the feasibility of an education-focused Mediterranean diet intervention among patients with MPN. Experimental Design: We randomly assigned patients with MPN to either a Mediterranean diet or standard U.S. Dietary Guidelines for Americans (USDA). Groups received equal but separate education with registered dietician counseling and written dietary resources. Patients were prospectively followed for feasibility, adherence, and symptom burden assessments. Biological samples were collected at four timepoints during the 15-week study to explore changes in inflammatory biomarkers and gut microbiome. Results: The Mediterranean diet was as easy to follow for patients with MPN as the standard USDA diet. Approximately 80% of the patients in the Mediterranean diet group achieved a Mediterranean Diet Adherence Score of ≥8 throughout the entire active intervention period, whereas less than 50% of the USDA group achieved a score of ≥8 at any timepoint. Improvement in symptom burden was observed in both diet groups. No significant changes were observed in inflammatory cytokines. The diversity and composition of the gut microbiome remained stable throughout the duration of the intervention. Conclusions: With dietician counseling and written education, patients with MPN can adhere to a Mediterranean eating pattern. Diet interventions may be further developed as a component of MPN care, and potentially incorporated into the management of other hematologic conditions. Significance: Diet is a central tenant of management of chronic conditions characterized by subclinical inflammation, such as cardiovascular disease, but has not entered the treatment algorithm for clonal hematologic disorders. Here, we establish that a Mediterranean diet intervention is feasible in the MPN patient population and can improve symptom burden. These findings warrant large dietary interventions in patients with hematologic disorders to test the impact of diet on clinical outcomes.